In a report released today, Robert Burns from H.C. Wainwright reiterated a Buy rating on Atara Biotherapeutics (ATRA – Research Report), with a price target of $28.00. The company’s shares closed yesterday at $2.27.
According to TipRanks, Burns is an analyst with an average return of -29.4% and a 19.64% success rate. Burns covers the Healthcare sector, focusing on stocks such as Replimune Group, GT Biopharma, and BioNTech SE.
Currently, the analyst consensus on Atara Biotherapeutics is a Moderate Buy with an average price target of $21.30, representing an 838.33% upside. In a report released yesterday, Mizuho Securities also maintained a Buy rating on the stock with a $31.00 price target.
See the top stocks recommended by analysts >>
Based on Atara Biotherapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $74.77 million. In comparison, last year the company had a net profit of $18.47 million
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ATRA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atara Biotherapeutics, Inc. operates as a clinical stage company, which engages in the development of novel therapeutics for patients with cancer, autoimmune, and viral diseases. Its pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in South San Francisco, CA.
Read More on ATRA:
